Allogene Therapeutics (ALLO) Net Cash Flow (2018 - 2026)

Allogene Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at -$21.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 34.75% year-over-year to -$21.4 million; the TTM figure through Mar 2026 stood at -$12.1 million (down 41.5% YoY), while the FY2025 annual figure was -$23.5 million, down 196.46% from the prior year.
• Net Cash Flow came in at -$21.4 million for Q1 2026 at Allogene Therapeutics, down from $13.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $119.6 million in Q2 2024 to a low of -$119.4 million in Q3 2024.
• A 5-year average of -$8.4 million and a median of -$12.5 million in 2022 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 288.89% in 2023 and fell as far as 294.36% in 2023.
• Allogene Therapeutics' Net Cash Flow stood at -$12.5 million in 2022, then jumped by 211.69% to $13.9 million in 2023, then surged by 72.4% to $24.0 million in 2024, then plunged by 42.15% to $13.9 million in 2025, then tumbled by 254.11% to -$21.4 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$21.4 million, $13.9 million, and -$14.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison